Crinetics Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Crinetics Pharmaceuticals (San Diego, CA): 1 reconciled FDA prescription therapies, $0 2024 CMS Part D & Medicaid spend, and $24,165 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterSan Diego, CA
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2044-01-01
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
California HCAI SB 17 FilingsSpecialty launch notice ($24,165 intro WAC)